Year-end Sale % OFF 
Abstract
Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor. The survival of advanced HCC is very poor. In this case study, we describe the treatment of a 69-year-old woman diagnosed with massive hepatocellular carcinoma, the use of lenvatinib in combination with nivolumab injection in the preoperative adjuvant treatment of advanced massive hepatocellular carcinoma, and the final taking extended right hepatectomy. Molecular targeted drugs and immunotherapy controlled patient’s condition to create time and conditions for surgery. After surgery, AFP was greatly reduced, no recurrence of the residual liver and no metastasis in the distance. This treatment is the gospel of patients with advanced liver cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
